TY - JOUR
T1 - RNA nanomedicines
T2 - The next generation drugs?
AU - Singh, Manu Smriti
AU - Peer, Dan
N1 - Funding Information:
This work was supported in part by grants from Dotan Hematology Center At Tel Aviv University Grant # 0604456012, The Lewis Family Trust, Israel Science Foundation (award #181/10), the I-CORE Program of the Planning and Budgeting Committee and The Israel Science Foundation (grant no. 41/11 ) and the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative and by The Leona M. and Harry B. Helmsley Nanotechnology Research Fund awarded to D.P.
Publisher Copyright:
© 2016 Elsevier Ltd.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - RNA therapeutics could represent the next generation personalized medicine. The variety of RNA molecules that can inhibit the expression of any mRNA using, for example, RNA interference (RNAi) strategies, or increase the expression of a given protein using modified mRNA together with new gene editing strategies open new avenues for manipulating the fate of diseased cells while leaving healthy cells untouched. In addition, these therapeutic RNA molecules can maximize the treatment of diseases and minimize its adverse effects. Yet, the promise of RNA therapeutics is hindered by the lack of efficient delivery strategies to selectively target these molecules into specific cells. Herein, we will focus on the challenges and opportunities of the delivery of therapeutic RNAi molecules into cancer cells with special emphasis on solid tumors. Solid tumors represent more than 80 percent of cancers and some are very challenging to treat, not merely due to physiological barriers but also since the tumor microenvironment (TME) is a complex milieu of accessory cells besides the cancerous cells. In this review, we will highlight various limiting factors to successful delivery, current clinical achievements and future outlook focusing on RNAi therapeutics to the TME.
AB - RNA therapeutics could represent the next generation personalized medicine. The variety of RNA molecules that can inhibit the expression of any mRNA using, for example, RNA interference (RNAi) strategies, or increase the expression of a given protein using modified mRNA together with new gene editing strategies open new avenues for manipulating the fate of diseased cells while leaving healthy cells untouched. In addition, these therapeutic RNA molecules can maximize the treatment of diseases and minimize its adverse effects. Yet, the promise of RNA therapeutics is hindered by the lack of efficient delivery strategies to selectively target these molecules into specific cells. Herein, we will focus on the challenges and opportunities of the delivery of therapeutic RNAi molecules into cancer cells with special emphasis on solid tumors. Solid tumors represent more than 80 percent of cancers and some are very challenging to treat, not merely due to physiological barriers but also since the tumor microenvironment (TME) is a complex milieu of accessory cells besides the cancerous cells. In this review, we will highlight various limiting factors to successful delivery, current clinical achievements and future outlook focusing on RNAi therapeutics to the TME.
UR - http://www.scopus.com/inward/record.url?scp=84953310429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953310429&partnerID=8YFLogxK
U2 - 10.1016/j.copbio.2015.12.011
DO - 10.1016/j.copbio.2015.12.011
M3 - Review article
C2 - 26773301
AN - SCOPUS:84953310429
SN - 0958-1669
VL - 39
SP - 28
EP - 34
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
ER -